Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The drug name "[123I] MNI-308" does not correspond to a clearly identifiable or widely recognized pharmaceutical compound in publicly available databases. The prefix "[123I]" strongly suggests that it is a radiopharmaceutical, meaning it is a drug labeled with the radioactive isotope Iodine-123. Such compounds are typically used in nuclear medicine for diagnostic imaging, as Iodine-123 emits gamma rays detectable by SPECT (Single-Photon Emission Computed Tomography) scanners. Common examples of Iodine-123 labeled radiopharmaceuticals include Iobenguane I-123 (123I-MIBG), used for imaging neuroendocrine tumors, and Ioflupane I-123 (123I-FP-CIT), used for dopamine transporter imaging in neurological disorders. However, without further context or a direct link in scientific literature or drug databases, the specific chemical identity, mechanism of action, developer, or primary indication of a compound precisely named "MNI-308" labeled with Iodine-123 cannot be determined. It is possible that "MNI-308" is an internal research code, an experimental compound, or a less common designation not widely documented.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [123I] MNI-308.